Practical Management of Patients with Atopic Dermatitis on Dupilumab

INTRODUCTION: Dupilumab is approved to treat moderate-to-severe atopic dermatitis (AD) in several countries in patients as young as 6 years of age. Since its approval, practical issues related to the use of dupilumab for AD have arisen, with particular interest in transitioning from current therapie...

Descripción completa

Detalles Bibliográficos
Autores principales: Papp, Kim A., Hong, Chih-ho, Lansang, M. Perla, Turchin, Irina, Adam, David N., Beecker, Jennifer R., Bissonnette, Robert, Gooderham, Melinda J., Jack, Carolyn, Joseph, Marissa, Lynde, Charles W., Shear, Neil H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435113/
https://www.ncbi.nlm.nih.gov/pubmed/34510403
http://dx.doi.org/10.1007/s13555-021-00586-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435113/
https://www.ncbi.nlm.nih.gov/pubmed/34510403
http://dx.doi.org/10.1007/s13555-021-00586-w

Ejemplares similares